CANbridge Pharmaceuticals (1228) Fundamentals 2026 — P/E 36.1x, Revenue Analysis | SniperIQ

.98 on the HKSE. This SniperIQ fundamentals page covers CANbridge Pharmaceuticals's valuation (P/E 36.1x), profitability (net margin 29.6%), revenue (¥50M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is CANbridge Pharmaceuticals's market cap?

CANbridge Pharmaceuticals (1228) has a market capitalization of approximately HK$841M, trading at HK

.98 on the HKSE. Market cap moves with the live share price.

What is CANbridge Pharmaceuticals's P/E ratio?

CANbridge Pharmaceuticals's trailing twelve-month P/E ratio is 36.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is CANbridge Pharmaceuticals?

CANbridge Pharmaceuticals runs a net profit margin of 29.6%, a gross margin of 73.1%, and an operating margin of -185.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does CANbridge Pharmaceuticals generate?

CANbridge Pharmaceuticals reported revenue of ¥50M for fiscal year 2025, with net income of ¥15M and earnings per share (EPS) of 0.0282. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does CANbridge Pharmaceuticals pay a dividend?

CANbridge Pharmaceuticals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is CANbridge Pharmaceuticals financially healthy?

CANbridge Pharmaceuticals carries a debt-to-equity ratio of -0.05x and a current ratio of 0.24x, with a market beta of -0.09. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is CANbridge Pharmaceuticals a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For CANbridge Pharmaceuticals (1228) the key facts are: market cap HK$841M, P/E 36.1x, revenue ¥50M, 52-week range 0.67-3.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.